MAP2K7 and breast cancer: Hoeflich KP, O’Brien C, Boyd Z, Cavet G et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009 Jul 15; 15(14):4649–64.